A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

Summary

This was a 52-week, multicentric, phase II, pilot study conducted in 40 subjects with early-onset Alzheimer's disease (AD) to evaluate safety, tolerability and clinical efficacy of subcutaneous (sc) interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] in the treatment of AD by comparing the neuropsychological performance changes into placebo and treatment arms from screening/baseline to 52 week.

Timeline

Start

2004-11

Primary completion

2008-05

Completion

2008-05

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Rebif 22 Mcg vs Placebo; p = 0.64; t-test, 2 sided NCT01075763 ↗

Drugs

Indications